Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study

• Published in: The lancet oncology Vol. 16; no. 2; pp. 152 - 160
• Main Authors: Ryan, Charles J, Smith, Matthew R, Fizazi, Karim, Saad, Fred, Mulders, Peter F A, Sternberg, Cora N, Miller, Kurt, Logothetis, Christopher J, Shore, Neal D, Small, Eric J, Carles, Joan, Flaig, Thomas W, Taplin, Mary-Ellen, Higano, Celestia S, de Souza, Paul, de Bono, Johann S, Griffin, Thomas W, De Porre, Peter, Yu, Margaret K, Park, Youn C, Li, Jinhui, Kheoh, Thian, Naini, Vahid, Molina, Arturo, Rathkopf, Dana E
• Format: Journal Article
• Language: English
• Published: England Elsevier Ltd 01.02.2015; Elsevier Limited
• Subjects: Aged; Androstenes - therapeutic use; Antineoplastic Agents, Hormonal - therapeutic use; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms - drug therapy; Bone Neoplasms - mortality; Bone Neoplasms - secondary; Cancer and Oncology; Cancer och onkologi; Chemotherapy; Clinical Medicine; Disease Progression; Double-Blind Method; Drug therapy; Follow-Up Studies; Hematology, Oncology and Palliative Medicine; Humans; Klinisk medicin; Male; Medical and Health Sciences; Medical research; Medicin och hälsovetenskap; Neoplasm Staging; Prednisone - therapeutic use; Prognosis; Prostate cancer; Prostatic Neoplasms, Castration-Resistant - drug therapy; Prostatic Neoplasms, Castration-Resistant - mortality; Prostatic Neoplasms, Castration-Resistant - pathology; Survival Rate

Abiraterone acetate plus prednisone significantly improved radiographic progression-free survival compared with placebo plus prednisone in men with chemotherapy-naive castration-resistant prostate cancer at the interim analyses of the COU-AA-302 trial. Here, we present the prespecified final analysi...